Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A

4.02
HKD
0.00
(0.00%)
0.10EPS
37.93P/E
15.85BMarket Cap
Apr 01Next Earn

Total Valuation

HKD

As of September 30, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H carries a market capitalization of 15.85B, placing it among publicly traded companies globally. Its enterprise value stands at 14.45B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap15.85B
Enterprise Value14.45B

Important Dates

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H's next confirmed earnings release is scheduled for April 1, 2027.

Earnings Date4/1/2027

Share Statistics

As of September 30, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 3.91B shares outstanding.

Shares Outstanding3.91B

Valuation Ratios

As of September 30, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H trades at a trailing price-to-earnings ratio of 37.93. The price-to-sales ratio is 1.42, and the price-to-book ratio stands at 1.12.

PE Ratio37.93
PS Ratio1.42
PB Ratio1.12
P/TBV Ratio1.42

Enterprise Valuation

As of September 30, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H trades at an EV/EBITDA multiple of 70.46 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 70.46 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 14.45B versus a market cap of 15.85B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.43
EV / EBITDA70.46
EV / EBIT70.46

Financial Position

As of September 30, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H maintains a current ratio of 2.34, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.04, indicating elevated leverage, while an interest coverage ratio of 3.30 demonstrates adequate ability to service its debt obligations.

Current Ratio2.34
Quick Ratio1.02
Debt / Equity25.04
Debt / EBITDA17.28
Interest Coverage3.30

Financial Efficiency

HKD

Over the twelve months ended September 30, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H posted a return on equity (ROE) of 1.57, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 1.12, measuring how efficiently the asset base is converted into earnings. The company generates approximately 2.77M in revenue per employee across its workforce of 2,150.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.81 indicates how many times Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)1.57
Return on Assets (ROA)1.12
Revenue Per Employee2.77M
Employee Count2,150.00
Inventory Turnover0.81

Taxes

HKD

Over the twelve months ended September 30, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H recorded an income tax benefit of -16.65M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 197.90M, leaving 222.12M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax-16.65M

Stock Price Statistics

HKD

As of the close on November 17, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H's stock has declined approximately 27.70% over the past 52 weeks. The 50-day moving average sits at 3.99, while the 200-day moving average is 4.50.

52-Week Price Change-27.70%
50-Day Moving Average3.99
200-Day Moving Average4.50

Income Statement

HKD

Over the twelve months ended September 30, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H generated 5.95B in revenue and converted that into 222.12M in net income, yielding earnings per share of 0.10. EBITDA reached 205.08M, while operating income came in at 689.25M.

Revenue5.95B
Gross Profit2.02B
Operating Income689.25M
Pretax Income197.90M
Net Income222.12M
EBITDA205.08M
EBIT205.08M
Earnings Per Share (EPS)0.10

Balance Sheet

HKD

As of September 30, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H holds 5.00B in cash and equivalents against 3.54B in total debt, resulting in a net debt position of 1.60B. Total book value stands at 14.09B, with working capital of 6.60B providing operational flexibility.

Cash & Cash Equivalents5.00B
Total Debt3.54B
Net Debt1.60B
Equity (Book Value)14.09B
Book Value Per Share3.61
Working Capital6.60B

Cash Flow

HKD

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-123.52M

Margins

Over the twelve months ended September 30, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H posted a gross margin of 33.96, reflecting its pricing power and cost economics. The operating margin of 11.59 and net profit margin of 3.74 provide insight into operational efficiency.

Gross Margin33.96
Operating Margin11.59
Pretax Margin3.33
Profit Margin3.74
EBITDA Margin3.45

Dividends & Yields

HKD

Over the twelve months ended September 30, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H paid dividends of 0.14 per share. The dividend payout ratio of 144.66 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.41, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H shareholders.

Dividend Per Share0.14
Payout Ratio144.66
Shareholder Yield3.41

Scores

As of September 30, 2026, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has an Altman Z-Score of 3.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.19